EGF receptor-related protein (ERRP) inhibits invasion of colon cancer cells and tubule formation by endothelial cells in vitro

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 1029-1037

  Rishi, Arun K ^a   Parikh, Rakesh ^a   Wali, Anil ^a   Durko, Lukasz ^a   Zhang, Liyue ^a   Yu, Yingjie ^a   Majumdar, Adhip P N ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; EGF receptor; EGFR signal transduction; Growth factors

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CANCER GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; PROTEIN P21; RAC1 PROTEIN; RAF PROTEIN; RAS PROTEIN;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

CAPILLARIES; COLONIC NEOPLASMS; CYCLIN B; ENDOTHELIAL CELLS; ENZYME ACTIVATION; EXONUCLEASES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FOCAL ADHESION KINASE 1; GLYCOPROTEINS; HCT116 CELLS; HUMANS; MAP KINASE KINASE 1; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT PROTEINS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 33645825443     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Glenney JR: Tyrosine-phosphorylated proteins: mediators of signal transduction from the tyrosine kinases. Biochim Biophys Acta 1134: 113-127, 1992.
2. Lohrisch C and Piccart M: An overview of HER-2. Sem Oncol 28(Suppl. 18): 3-11, 2001.
3. Krischbaum MH and Yarden Y: The ErbB/HER family of receptor tyrosine kinases: a potential target for chemoprevention of epithelial neoplasms. J Cell Biochem Suppl 34: 52-60, 2000.
4. Porter AC and Vaillancourt RR: Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 15: 1343-1352, 1998.
5. Kapitanovic S, Radosavic S, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Primorac D, Sonicki Z and Spaventi R: The expression of p185 HER-2/neu correlates with the stage of disease and survival in colorectal cancer. Gastroenterol 112: 1103-1113, 1997.
6. Laskin JJ and Sandler AB: Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 30: 1-17, 2004.
7. Ritter CA and Arteaga CL: The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Sem Oncol 30(Suppl. 1): 3-11, 2003.
8. Pavelic K, Banjac Z, Pavelic J and Spaventi D: Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 13: 1133-1138, 1993.
9. Grunwald V and Hidalgo M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95: 851-867, 2003.
10. Allen LF, Lenehan PF, Eiseman IA, Elliot WL and Fry DW: Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Sem Oncol 29(Suppl. 11): 11-21, 2002.
11. Ciardiello F: Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 1: 221-234, 2005.
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman and Haber DA: Activating mutations in epidermal growth factor receptor underlying responsiveness if non-small-cell lung cancer to geftinib. N Eng J Med 350: 2129-2139, 2004.
13. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers W, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
14. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med 2: 1-11 2005.
15. Yu Y, Rishi A, Turner J, Liu D, Black E, Moshier JA and Majumdar APN: Cloning of a novel EGFR related peptide: a putative negative regulator of EGFR. Am J Physiol Cell Physiol 280: C1083-C1089, 2001.
16. Xu H, Yu Y, Marciniak D, Rishi AK, Sarkar FH, Kucuk O and Majumdar APN: Epideremal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 4: 435-442, 2005.
17. Majumdar APN: Therapeutic potential of EGFR-related protein, a universal EGFR family antagonist. Future Oncol 1: 235-245, 2005.
18. Zhang Y, Banerjee S, Wang Z, Xu H, Zhang L, Mohammad R, Aboukameel A, Adsay NV, Che M, Buruazzese JL, Majumdar APN and Sarkar FH: Anti-cellular and anti-tumor activity of EGFR-related protein is mediated by inactivation of erbB receptors and NF-κB in pancreatic cancer. Cancer Res, in press.
19. Marciniak DJ, Moragoda L, Mohammad R, Yu Y, Nagothu KK, Aboukameel A, Sarkar FH, Adsay, V, Rishi AK and Majumdar APN: Epidermal growth factor receptor related protein (ERRP): a potential therapeutic agent for colorectal cancer. Gastroenterlogy 124: 1337-1347, 2003.
20. Levi E, Mohammad R, Kodali U, Marciniak D, Reddy S, Sarkar FH, Rishi AK and Majumdar APN: EGF-receptor related protein causes cell cycle arrest and induces apoptosis of colon cancer cells in vitro and in vivo. Anticancer Res 24: 2885-2892, 2004.
21. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
22. Marciniak DJ, Rishi AK, Sarkar FH and Majumdar APN: Epidermal growth factor receptor-related peptide (ERRP) inhibits growth of PC-3 prostate cancer cells. Mol Cancer Ther 24: 1615-1621, 2004.
23. Rishi AK, Zhang L, Boyanapalli M, Wali A, Mohammad RM, Yu Y, Fontana JA, Hatfield JS, Dawson MI, Majumdar APN and Reichert U: Identification and characterization of a cell-cycle and apoptosis regulatory protein (CARP)-1 as a novel mediator of apoptosis signaling by retinoid CD437. J Biol Chem 278: 33422-33435, 2003.
24. Moon WS, Chai J, Yang JT, Tarnawski AS and Majumdar APN: Reduction of epidermal growth factor receptor related protein expression in gastric cancer: a key to cancer growth and differentiation. Gut 54: 201-206, 2005.
25. Zhang Y, Banerjee S, Wang Zhi-wei, Marciniak DJ, Majumdar APN and Sarkar FH: Epidermal growth factor receptor related protein (ERRP) inhibits cell growth and induces apoptosis of BxPC-3 pancreatic cancer cells. Cancer Res 65: 3877-3882, 2005.
26. Fox SB, Gatter KC and Harris AL: Tumor angiogenesis. J Pathol 179: 232-237, 1996.
27. De Jong JS, van Diest PJ, van der Valk P et al: Expression of growth factors, growth factor-inhibiting factors, and their receptors in invasive breast cancer II: correlations with proliferation and angiogenesis. J Pathol 184: 53-57, 1998.
28. Dvorak HF, Brown LF, Detmar M et al: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
29. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 1029-1039, 1996.
30. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
31. Donovan D, Brown NJ, Bishop ET and Lewis CE: Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 4: 113-121, 2001.
32. Fontanini G, De Laurentiis M, Vignati S et al: Evaluation of epidermal growth factor-related growth factor and receptors and of neoangiogenesis in completely resected stage I-III non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4: 241-249, 1998.
33. Viloria Petit AM, Rak J, Hung M-C et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151: 1523-1530, 1997.
34. Perrotte P, Matsumoto T, Inoue K et al: Chimeric monoclonal antibody (Mab) C-225 to the epidermal growth factor receptor (EGF-R) antibody inhibits angiogenesis in human transitional cell carcinoma (TCC). Proc Am Assoc Cancer Res 39: 316, 1998.
35. Schreiber AB, Winkler ME and Derynck R: Transforming growth factor-α: a more potent angiogenic mediator than epidermal growth factor. Science 232: 1250-1253, 1986.
36. Datta SR, Brunet A and Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927, 1999.